Zavesca Related Published Studies
Well-designed clinical trials related to Zavesca (Miglustat)
Evaluation of miglustat treatment in patients with type III mucopolysaccharidosis: a randomized, double-blind, placebo-controlled study. [2011.11]
Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. [2010.04]
Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment. [2009.06]
Randomized, controlled trial of miglustat in Gaucher's disease type 3. [2008.11]
Well-designed clinical trials possibly related to Zavesca (Miglustat)
The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. [1994.02]
Other research related to Zavesca (Miglustat)
The videofluoroscopic swallowing study shows a sustained improvement of dysphagia in children with Niemann-Pick disease type C after therapy with miglustat. [2011.03]
Clinical experience with miglustat therapy in pediatric patients with Niemann-Pick disease type C: a case series. [2010.04]
Changes in the atherogenic profile of patients with type 1 Gaucher disease after miglustat therapy. [2010.04]
Long-term miglustat therapy in children with Niemann-Pick disease type C. [2010.03]
Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project. [2009.12]
Miglustat in patients with Niemann-Pick disease Type C (NP-C): a multicenter observational retrospective cohort study. [2009.11]
Long-Term Miglustat Therapy in Children With Niemann-Pick Disease Type C. [2009.10.12]
Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme. [2009.09]
Pharmacokinetics, safety and tolerability of miglustat in the treatment of pediatric patients with GM2 gangliosidosis. [2009.08]
A cystic fibrosis respiratory epithelial cell chronically treated by miglustat acquires a non-cystic fibrosis-like phenotype. [2009.08]
Airway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice. [2009.06.01]
24 month-treatment with miglustat of three patients with Niemann-Pick disease type C: follow up using brain spectroscopy. [2009.02]
Goal-oriented therapy with miglustat in Gaucher disease. [2009.01]
New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat. [2009]
Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat. [2008.07]
Motion analysis of a child with Niemann-Pick disease type C treated with miglustat. [2008.01]
Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. [2007.10.01]
Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase. [2007.10]
Treatment of Niemann-Pick disease type C in two children with miglustat: initial responses and maintenance of effects over 1 year. [2007.10]
Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. [2007.09]
Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. [2007.08]
Effective treatment of an elderly patient with Gaucher's disease and Parkinsonism: a case report of 24 months' oral substrate reduction therapy with miglustat. [2007.08]
Oral maintenance clinical trial with miglustat for type 1 Gaucher disease: switch from or combination with intravenous enzyme replacement. [2007.07.03]
Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination. [2007.07]
Miglustat has no apparent effect on spermatogenesis in normal men. [2007.03]
The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. [2007.03]
Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher's disease. [2006.05]
Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders. [2006.01]
Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. [2005.11]
An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. [2005.08]
Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C. [2004.08]
Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. [2004]
Miglustat. Oxford GlycoSciences/Actelion. [2003.04]
Substrate reduction therapy: miglustat as a remedy for symptomatic patients with Gaucher disease type 1. [2003.02]
The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. [2003]
Miglustat. [2003]
Other possibly related research studies
Substrate reduction therapy for lysosomal storage diseases. [2005.03]
Computerized cognitive testing in patients with type I Gaucher disease: effects of enzyme replacement and substrate reduction. [2005.02]
Gaucher disease and the clinical experience with substrate reduction therapy. [2003.05.29]
Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease. [2003.05.29]
Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. [2003.04]
Glycolipid depletion in antimicrobial therapy. [2003.01]
Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis. [2002.10]
The combination of interferon alpha-2b and n-butyl deoxynojirimycin has a greater than additive antiviral effect upon production of infectious bovine viral diarrhea virus (BVDV) in vitro: implications for hepatitis C virus (HCV) therapy. [2002.09]
Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. [2002.03]
pH-sensitive liposomes are efficient carriers for endoplasmic reticulum-targeted drugs in mouse melanoma cells. [2002.05.10]
Critical role for glycosphingolipids in Niemann-Pick disease type C. [2001.08.21]
N -butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours. [2001.04.20]
Substrate reduction therapy for glycosphingolipid storage disorders. [2001.03]
Stemming the tide: glycosphingolipid synthesis inhibitors as therapy for storage diseases. [2000.12]
Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. [2001.01.01]
Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. [2000.04.29]
N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. [2000.04.01]
Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. [1999.05.25]
Biology and potential strategies for the treatment of GM2 gangliosidoses. [1998.04]
Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. [1997.04.18]
Species dependent esterase activities for hydrolysis of an anti-HIV prodrug glycovir and bioavailability of active SC-48334. [1995.08]
Gateways to clinical trials. [2003.05]
Gaucher disease: multiple lessons from a single gene disorder. [2006.04]
Emerging strategies for the treatment of hereditary metabolic storage disorders. [2006.06]
Therapeutic goals in Gaucher disease. [2006.03]
[Clinical study of the French cohort of Gaucher disease patients] [2006.03]
Glycolipid receptor depletion as an approach to specific antimicrobial therapy. [2006.05]
Substrate reduction therapy in the infantile form of Tay-Sachs disease. [2006.01.24]
Long-term non-hormonal male contraception in mice using N-butyldeoxynojirimycin. [2006.05]
Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. [2005.10]
The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases. [1995.12.15]
Gateways to clinical trials. [2006.01]
Substrate reduction therapy of glycosphingolipid storage disorders. [2006.04]
[Iminosugars: current and future therapeutic applications] [2007.01]
Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment. [2007.02]
Pharmacotherapeutic strategies using small molecules for the treatment of glycolipid lysosomal storage disorders. [2007.03]
[Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment.] [2007.05.09]
[Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment.] [2007.05.10]
Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease. [2007.09.28]
[Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment.] [2007.12]
[Organization of Gaucher disease management in France] [2007.10]
[Current development and usefulness of biomarkers for Gaucher disease follow up] [2007.10]
[Therapeutic objectives in Gaucher disease] [2007.10]
Substrate deprivation therapy: a new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases. [2007]
Gateways to clinical trials. [2008.01]
N-butyldeoxynojirimycin causes weight loss as a result of appetite suppression in lean and obese mice. [2008.02]
Differential sensitivity of mouse strains to an N-alkylated imino sugar: glycosphingolipid metabolism and acrosome formation. [2008.06]
Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis. [2008.06]
New perspectives in non-hormonal male contraception. [2008.03]
Substrate reduction therapy. [2008.04]
Gaucher disease: unmet treatment needs. [2008.04]
Splenic nodules in paediatric Gaucher disease treated by enzyme replacement therapy. [2008.06]
N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery. [2008.10.01]
The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts. [2009.06]
Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice. [2010.06]
Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy. [2010.06]
Gateways to clinical trials. [2009.10]
Eye movement and diffusion tensor imaging analysis of treatment effects in a Niemann-Pick Type C patient. [2010.03]
Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. [2010.01.15]
[Gaucher's disease in Rennes University hospital: a 10-year retrospective study] [2009.10]
|
